{"id":58775,"date":"2026-05-22T09:02:53","date_gmt":"2026-05-22T07:02:53","guid":{"rendered":"https:\/\/setterwalls.se\/?post_type=articles&p=58775"},"modified":"2026-05-22T09:02:54","modified_gmt":"2026-05-22T07:02:54","slug":"the-swedish-dental-and-pharmaceutical-benefits-agency-proposes-new-regulations-on-applications-for-subsidies-and-the-pricing-of-medicinal-products","status":"publish","type":"articles","link":"https:\/\/setterwalls.se\/en\/article\/the-swedish-dental-and-pharmaceutical-benefits-agency-proposes-new-regulations-on-applications-for-subsidies-and-the-pricing-of-medicinal-products\/","title":{"rendered":"The Swedish Dental and Pharmaceutical Benefits Agency proposes new regulations on applications for subsidies and the pricing of medicinal products"},"content":{"rendered":"
\n
\n
\n
\n
\n

On 20 March, the Swedish Dental and Pharmaceutical Benefits Agency (TLV) issued a consultation document containing proposals for new regulations on applications for subsidies and the pricing of medicinal products (ref. no. 01020\/2026), along with an accompanying impact assessment. The proposal means that the current regulations and general guidelines (TLVFS 2008:2) on applications and decisions regarding medicinal products will be repealed and replaced by a new regulatory framework. The new regulations also amend the Swedish Dental and Pharmaceutical Benefits Agency\u2019s regulations (TLVFS 2003:2) on non-prescription medicinal products under the Act (2002:160) on Pharmaceutical Benefits, etc. The new regulations are proposed to enter into force on 1 July 2026.<\/strong><\/p>\n

Background<\/strong><\/p>\n

The current regulations were issued in 2008 and have been amended on several occasions. Nonetheless, the TLV considers that several parts of the regulations are outdated and need to be revised to reflect rapid developments in the field of medicinal products, including new treatment options and higher societal costs for medicinal products. Against this background, on 22 December 2025, the TLV referred a first proposal for new general guidelines on the subsidisation and pricing of medicinal products, along with the repeal of existing regulations and general advice (ref. no. 4517\/2025) (the \u201cFirst Referral<\/strong>\u201d). You can read more about this referral in our article\u00a0here<\/a>.<\/p>\n

In the First Referral, the TLV proposed that the requirements for what an application for subsidies and pricing must contain should be set out in an appendix to the new general guidelines and in the handbook for companies applying for reimbursement and pricing of medicines (the \u201dCompany Handbook<\/strong>\u201d), rather than in binding regulations. The overall aim of the reform is to create a more effective regulatory framework that provides greater predictability and transparency and facilitates implementation for government agencies, applicant companies and other stakeholders.<\/p>\n

Several consultation bodies responded to the First Referral by pointing out that requirements that are binding on individual companies should not be regulated through non-binding instruments such as general guidelines or the Company Handbook but must instead have a clear legal basis in binding regulations. To accommodate these comments, the TLV has now issued the present referral, in which the binding application requirements have been moved from the appendix to the general guidelines and the Company Handbook and into new, binding regulations.<\/p>\n

In light of this, the TLV proposes:<\/p>\n